{
    "organizations": [],
    "uuid": "93ade468a406039a565001ec03d6ea18924e0d46",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kamada-announces-data-from-phase-2/brief-kamada-announces-data-from-phase-2-clinical-trial-of-intravenous-alpha-1-antitrypsin-treatment-for-prevention-of-lung-transplant-rejection-idUSASB0C00Z",
    "ord_in_thread": 0,
    "title": "BRIEF-Kamada Announces Data From Phase 2 Clinical Trial Of Intravenous Alpha-1 Antitrypsin Treatment For Prevention Of Lung Transplant Rejection",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Kamada Ltd:\n* KAMADA ANNOUNCES INTERIM RESULTS FROM PHASE 2 CLINICAL TRIAL OF INTRAVENOUS ALPHA-1 ANTITRYPSIN TREATMENT FOR PREVENTION OF LUNG TRANSPLANT REJECTION\n* KAMADA LTD - TOP-LINE RESULTS FROM PHASE 2 TRIAL OF ALPHA-1 ANTITRYPSIN ANTICIPATED IN H2 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T20:10:00.000+02:00",
    "crawled": "2018-01-09T17:12:09.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "kamada",
        "ltd",
        "kamada",
        "announces",
        "interim",
        "result",
        "phase",
        "clinical",
        "trial",
        "intravenous",
        "antitrypsin",
        "treatment",
        "prevention",
        "lung",
        "transplant",
        "rejection",
        "kamada",
        "ltd",
        "result",
        "phase",
        "trial",
        "antitrypsin",
        "anticipated",
        "h2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}